EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation

Chara E S Spanou, Alexander P Wohl, Sandra Doherr, Annkatrin Correns, Niklas Sonntag, Steffen Lütke, Matthias Mörgelin, Thomas Imhof, Jan M Gebauer, Ulrich Baumann, Kay Grobe, Manuel Koch und 1 weitere

The FASEB Journal · 2023

DOI: 10.1096/fj.202200904r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Chara E S Spanou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Glycosaminoglycans, Bone Morphogenetic Protein 7. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone morphogenetic proteins (BMP) are powerful regulators of cellular processes such as proliferation, differentiation, and apoptosis. However, the specific molecular requirements controlling the bioavailability of BMPs in the extracellular matrix (ECM) are not yet fully understood. Our previous work showed that BMPs are targeted to the ECM as growth factor‐prodomain (GF‐PD) complexes (CPLXs) via specific interactions of their PDs. We showed that BMP‐7 PD binding to the extracellular microfibril component fibrillin‐1 renders the CPLXs from an open, bioactive V‐shape into a closed, latent ring shape. Here, we show that specific PD interactions with heparin/heparan sulfate glycosaminoglycans (GAGs) allow to target and spatially concentrate BMP‐7 and BMP‐9 CPLXs in bioactive V‐shape conformation. However, targeting to GAGs may be BMP specific, since BMP‐10 GF and CPLX do not interact with heparin. Bioactivity assays on solid phase in combination with interaction studies showed that the BMP‐7 PD protects the BMP‐7 GF from inactivation by heparin. By using transmission electron microscopy, molecular docking, and site‐directed mutagenesis, we determined the BMP‐7 PD‐binding site for heparin. Further, fine‐mapping of the fibrillin‐1‐binding site within the BMP‐7 PD and molecular modeling showed that both binding sites are mutually exclusive in the open V‐ versus closed ring‐shape conformation. Together, our data suggest that targeting exquisite BMP PD‐binding sites by extracellular protein and GAG scaffolds integrates BMP GF bioavailability in a contextual manner in development, postnatal life, and connective tissue disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycosaminoglycansBone Morphogenetic Protein 7HeparinFibrillin-1Molecular Docking SimulationBone Morphogenetic ProteinsHeparan SulfateProtein BindingBone Morphogenetic Protein 2

Stichwörter der Autor:innen

ELISA-style bioactivity assaybone morphogenetic proteincomplexgrowth factorheparan sulfateheparan sulfate proteoglycansheparinheparin affinity chromatographymolecular modelingnegative-staining transmission electron microscopyprodomainsurface plasmon resonancevascular endothelial growth factor

Substanzen

GlycosaminoglycansBone Morphogenetic Protein 7HeparinFibrillin-1Bone Morphogenetic ProteinsHeparan SulfateBone Morphogenetic Protein 2

Autor:innen und Institutionen

  • Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Colzyx AB, Lund, Sweden.
  • Medical Faculty, Institute for Dental Research and Oral Musculoskeletal Biology, University of Cologne, Cologne, Germany.
  • Institute of Biochemistry, University of Cologne, Cologne, Germany.

ORCID-Profile: Gerhard Sengle

Zitieren

APA

Spanou, C. E. S., Wohl, A. P., Doherr, S., Correns, A., Sonntag, N., Lütke, S., Mörgelin, M., Imhof, T., Gebauer, J. M., Baumann, U., Grobe, K., Koch, M., & Sengle, G. (2023). Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation. The FASEB Journal. https://doi.org/10.1096/fj.202200904r

Vancouver

Spanou CES, Wohl AP, Doherr S, Correns A, Sonntag N, Lütke S, et al. Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation. The FASEB Journal. 2023. doi:10.1096/fj.202200904r

BibTeX
@article{Spanou2023,
  author = {Spanou, Chara E S and Wohl, Alexander P and Doherr, Sandra and Correns, Annkatrin and Sonntag, Niklas and Lütke, Steffen and Mörgelin, Matthias and Imhof, Thomas and Gebauer, Jan M and Baumann, Ulrich and Grobe, Kay and Koch, Manuel and Sengle, Gerhard},
  title = {Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation},
  journal = {The FASEB Journal},
  year = {2023},
  doi = {10.1096/fj.202200904r}
}
Kostenlos starten →